177 related articles for article (PubMed ID: 38467432)
1. Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.
Kharasch ED; Lenze EJ
Drug Metab Dispos; 2024 Apr; 52(5):455-466. PubMed ID: 38467432
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants.
Wang PF; Neiner A; Kharasch ED
Drug Metab Dispos; 2020 Jun; 48(6):438-445. PubMed ID: 32238417
[TBL] [Abstract][Full Text] [Related]
3. Common Polymorphisms of CYP2B6 Influence Stereoselective Bupropion Disposition.
Kharasch ED; Crafford A
Clin Pharmacol Ther; 2019 Jan; 105(1):142-152. PubMed ID: 29756345
[TBL] [Abstract][Full Text] [Related]
4. The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity.
Gao LC; Liu FQ; Yang L; Cheng L; Dai HY; Tao R; Cao SP; Wang D; Tang J
Eur J Clin Pharmacol; 2016 Oct; 72(10):1205-1213. PubMed ID: 27439448
[TBL] [Abstract][Full Text] [Related]
5. Stereoselective Steady-State Disposition and Bioequivalence of Brand and Generic Bupropion in Adults.
Kharasch ED; Neiner A; Kraus K; Blood J; Stevens A; Miller JP; Lenze EJ
Clin Pharmacol Ther; 2020 Nov; 108(5):1036-1048. PubMed ID: 32386065
[TBL] [Abstract][Full Text] [Related]
6. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
Kirchheiner J; Klein C; Meineke I; Sasse J; Zanger UM; Mürdter TE; Roots I; Brockmöller J
Pharmacogenetics; 2003 Oct; 13(10):619-26. PubMed ID: 14515060
[TBL] [Abstract][Full Text] [Related]
7. Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition.
Wang PF; Sharma A; Montana M; Neiner A; Juriga L; Reddy KN; Tallchief D; Blood J; Kharasch ED
Br J Clin Pharmacol; 2022 Nov; 88(11):4881-4893. PubMed ID: 35538637
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data.
Høiseth G; Haslemo T; Uthus LH; Molden E
Ther Drug Monit; 2015 Oct; 37(5):589-93. PubMed ID: 25565674
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
Kharasch ED; Mitchell D; Coles R
J Clin Pharmacol; 2008 Apr; 48(4):464-74. PubMed ID: 18287571
[TBL] [Abstract][Full Text] [Related]
10. Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
Lv J; Hu L; Zhuo W; Zhang C; Zhou H; Fan L
Pharmacogenet Genomics; 2016 Feb; 26(2):80-7. PubMed ID: 26580670
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.
Hesse LM; He P; Krishnaswamy S; Hao Q; Hogan K; von Moltke LL; Greenblatt DJ; Court MH
Pharmacogenetics; 2004 Apr; 14(4):225-38. PubMed ID: 15083067
[TBL] [Abstract][Full Text] [Related]
12. Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.
Coles R; Kharasch ED
Pharm Res; 2008 Jun; 25(6):1405-11. PubMed ID: 18219560
[TBL] [Abstract][Full Text] [Related]
13. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects.
Kim H; Bae SK; Park SJ; Shim EJ; Kim HS; Shon JH; Liu KH; Shin JG
Br J Clin Pharmacol; 2010 Jul; 70(1):126-31. PubMed ID: 20642555
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy.
Fokina VM; Xu M; Rytting E; Abdel-Rahman SZ; West H; Oncken C; Clark SM; Ahmed MS; Hankins GD; Nanovskaya TN
Drug Metab Dispos; 2016 Nov; 44(11):1832-1838. PubMed ID: 27528039
[TBL] [Abstract][Full Text] [Related]
15. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
Robertson SM; Maldarelli F; Natarajan V; Formentini E; Alfaro RM; Penzak SR
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):513-9. PubMed ID: 18989234
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.
Loboz KK; Gross AS; Williams KM; Liauw WS; Day RO; Blievernicht JK; Zanger UM; McLachlan AJ
Clin Pharmacol Ther; 2006 Jul; 80(1):75-84. PubMed ID: 16815319
[TBL] [Abstract][Full Text] [Related]
17. Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes.
Zhu AZ; Zhou Q; Cox LS; Ahluwalia JS; Benowitz NL; Tyndale RF
Drug Metab Dispos; 2014 Nov; 42(11):1971-7. PubMed ID: 25187485
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.
Benowitz NL; Zhu AZ; Tyndale RF; Dempsey D; Jacob P
Pharmacogenet Genomics; 2013 Mar; 23(3):135-41. PubMed ID: 23344581
[TBL] [Abstract][Full Text] [Related]
19. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation.
Fan L; Wang JC; Jiang F; Tan ZR; Chen Y; Li Q; Zhang W; Wang G; Lei HP; Hu DL; Wang D; Zhou HH
Eur J Clin Pharmacol; 2009 Apr; 65(4):403-9. PubMed ID: 19066872
[TBL] [Abstract][Full Text] [Related]
20. Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status.
Gaebler AJ; Schneider KL; Stingl JC; Paulzen M
Pharmacogenomics J; 2020 Dec; 20(6):840-844. PubMed ID: 32475982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
